HMOX1 and cystic fibrosis: Recent evidence has shown that systemic administration of PP-007, a CO releasing/O2 transfer agent, rescues the PI3K/HO-1 axis in CF macrophages and decreases the hyperinflammatory response to LPS, suggesting the HO-1 pathway as a potential candidate therapeutic target (107).